 Anticipates initiation of Phase 1 clinical trials of PRV-002 during the Second Quarter of 2021 IRVINE, CA ACCESSWIRE March 2, 2021 Odyssey Group International, Inc. OTCQB:ODYY Odyssey, a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that it has closed the previously announced acquisition of drug candidate PRV-002, a novel neurosteroid being developed for the treatment of concussion mild traumatic brain injury mTBI, from Prevacus, Inc. Prevacus in an all-stock transaction. A comprehensive video of the drug, and a description of how it works is available on the Companys Youtube channel. 